Difficulty: Medium
Average Score: 77%
Practice
Which LDL-C-lowering drug class includes three yearly administrations via subcutaneous injection?
Correct answer
D
Rationale
D' is correct because siRNA therapy (e.g., inclisiran) lowers LDL-C with three yearly subcutaneous injections by silencing PCSK9 mRNA, per clinical trials. 'A' (PCSK9 mAbs) is every 2-4 weeks. 'B' (bempedoic acid) and 'C' (ezetimibe) are oral. Inclisiran's dosing is unique.